Seeking Alpha

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, ...
Seeking Alpha

Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements

TORRANCE, Calif., June 26, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has received Food and Drug Administration ...
MarketWatch

(PMZN) Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

The MarketWatch News Department was not involved in the creation of this content. STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a ...
Morningstar

Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, marketing, and sale of innovative treatments and therapies, including those for rare ...